Aspergillus - Revision history

Aidan at 11:18, 20 March 2024

2024-03-20T11:18:33Z

← Older revision		Revision as of 11:18, 20 March 2024
Line 238:		Line 238:
	**Halo sign on CT is present for about the first 7 days of disease in neutropenic patients		**Halo sign on CT is present for about the first 7 days of disease in neutropenic patients
	**Can also have nodules, pleural-based infarctions, or vacitation, as well as non-specific consolidation		**Can also have nodules, pleural-based infarctions, or vacitation, as well as non-specific consolidation
			**See review [[CiteRef::franquet2001sp]]
	**See review <ref>Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001 Jul-Aug;21(4):825-37. doi: [https://doi.org/10.1148/radiographics.21.4.g01jl03825 10.1148/radiographics.21.4.g01jl03825]. PMID: [https://pubmed.ncbi.nlm.nih.gov/11452056/ 11452056].</ref>

	==Management==		==Management==

Aidan: /* Diagnosis */

2023-04-14T20:15:48Z

Diagnosis

← Older revision		Revision as of 20:15, 14 April 2023
Line 224:		Line 224:
	**'''Galactomannan''' by EIA		**'''Galactomannan''' by EIA
	***Best-studied and most sensitive in HSCT patients		***Best-studied and most sensitive in HSCT patients
	***It is a ~~meleased~~ from the fungal cell wall on growth		***It is a released from the fungal cell wall on growth
	***Cutoff of 0.5 is good, 80% Sn and Sp (up to 90% in HSCT patients' serum)		***Cutoff of 0.5 is good, 80% Sn and Sp (up to 90% in HSCT patients' serum)
	***BAL is more sensitive, but prophylaxis decreases sensitivity		***BAL is more sensitive, but prophylaxis decreases sensitivity

Aidan: /* Chronic pulmonary aspergillosis (CPA) */

2022-12-13T15:56:02Z

Chronic pulmonary aspergillosis (CPA)

← Older revision		Revision as of 15:56, 13 December 2022
Line 149:		Line 149:
	*Management is mostly surgical		*Management is mostly surgical

	=== Chronic ~~pulmonary~~ ~~aspergillosis~~ (CPA) ===		=== Chronic Pulmonary Aspergillosis (CPA) ===

	* Inclues chronic cavitary pulmonary aspergillosis (CCPA), chronic necrotising pulmonary aspergillosis (CNPA), and chronic fibrosing aspergillosis		* Inclues chronic cavitary pulmonary aspergillosis (CCPA), chronic necrotising pulmonary aspergillosis (CNPA), and chronic fibrosing aspergillosis

Aidan: /* Allergic syndromes */

2022-12-13T15:55:53Z

Allergic syndromes

← Older revision		Revision as of 15:55, 13 December 2022
Line 136:		Line 136:
	*[[Keratitis]]		*[[Keratitis]]

	===Allergic ~~syndromes~~===		===Allergic Syndromes===

	====Allergic Bronchopulmonary Aspergillosis (ABPA)====		====Allergic Bronchopulmonary Aspergillosis (ABPA)====

Aidan: /* Clinical Manifestations */

2022-12-13T15:55:18Z

Clinical Manifestations

← Older revision		Revision as of 15:55, 13 December 2022
Line 147:		Line 147:

	*Can be ''Aspergillus'' or other molds		*Can be ''Aspergillus'' or other molds
	*~~Mangement~~ is mostly surgical		*Management is mostly surgical

	===Chronic ~~Cavitary~~ ~~Pulmonary Aspergillosis~~ (~~CCPA~~)===		=== Chronic pulmonary aspergillosis (CPA) ===

			* Inclues chronic cavitary pulmonary aspergillosis (CCPA), chronic necrotising pulmonary aspergillosis (CNPA), and chronic fibrosing aspergillosis

			==== Chronic Cavitary Pulmonary Aspergillosis (CCPA) ====
	*One or more cavities that can contain solid or liquid material or a fungal ball, usually following creation of multiple cavities from another process		*One or more cavities that can contain solid or liquid material or a fungal ball, usually following creation of multiple cavities from another process
	*May present with pulmonary or constitutional symptoms, including hemoptysis, dyspnea, and productive cough		*May present with pulmonary or constitutional symptoms, including hemoptysis, dyspnea, and productive cough
Line 160:		Line 163:
	**No or minimal immunocompromise		**No or minimal immunocompromise
	*Must rule out other causes of symptoms, including other causes of weight loss		*Must rule out other causes of symptoms, including other causes of weight loss

			==== Chronic Necrotising Pulmonary Aspergillosis (CNPA) ====

			==== Chronic Fibrosing Aspergillosis (CFA) ====

	===Invasive Aspergillosis===		===Invasive Aspergillosis===

Aidan: /* Diagnosis */

2022-12-13T15:48:16Z

Diagnosis

← Older revision		Revision as of 15:48, 13 December 2022
Line 231:		Line 231:
	**Halo sign on CT is present for about the first 7 days of disease in neutropenic patients		**Halo sign on CT is present for about the first 7 days of disease in neutropenic patients
	**Can also have nodules, pleural-based infarctions, or vacitation, as well as non-specific consolidation		**Can also have nodules, pleural-based infarctions, or vacitation, as well as non-specific consolidation
			**See review <ref>Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001 Jul-Aug;21(4):825-37. doi: [https://doi.org/10.1148/radiographics.21.4.g01jl03825 10.1148/radiographics.21.4.g01jl03825]. PMID: [https://pubmed.ncbi.nlm.nih.gov/11452056/ 11452056].</ref>

	==Management==		==Management==

Aidan at 14:54, 15 April 2022

2022-04-15T14:54:32Z

← Older revision		Revision as of 14:54, 15 April 2022
Line 341:		Line 341:
	**[[Itraconazole]] or [[voriconazole]]		**[[Itraconazole]] or [[voriconazole]]
	**If this fails, try IV [[micafungin]], [[caspofungin]], or [[amphotericin B]]		**If this fails, try IV [[micafungin]], [[caspofungin]], or [[amphotericin B]]
		⚫	**An RCT of [[itraconazole]] found that the relapse rate was significantly lower with 12 months of therapy compared to 6 months[[CiteRef::sehgal2022ef]]
	*If [[hemoptysis]], treat with [[tranexamic acid]], pulmonary artery embolization, or antifungal therapy		*If [[hemoptysis]], treat with [[tranexamic acid]], pulmonary artery embolization, or antifungal therapy
	*May need surgical resection if localized disease refractory to medical management		*May need surgical resection if localized disease refractory to medical management
Line 354:		Line 355:
	**[[Isuvaconazole]] may be superior to [[voriconazole]]		**[[Isuvaconazole]] may be superior to [[voriconazole]]
	*Duration 6-12 weeks depending on immunosuppression		*Duration 6-12 weeks depending on immunosuppression
⚫	**An RCT of [[itraconazole]] found that the relapse rate was significantly lower with 12 months of therapy compared to 6 months[[CiteRef::sehgal2022ef]]
	*Follow-up CT after a minimum of 2 weeks, or earlier if deterioration		*Follow-up CT after a minimum of 2 weeks, or earlier if deterioration
	*Non-pharmacologic management for neutropenic patients includes:		*Non-pharmacologic management for neutropenic patients includes:

Aidan at 14:53, 15 April 2022

2022-04-15T14:53:37Z

← Older revision		Revision as of 14:53, 15 April 2022
Line 354:		Line 354:
	**[[Isuvaconazole]] may be superior to [[voriconazole]]		**[[Isuvaconazole]] may be superior to [[voriconazole]]
	*Duration 6-12 weeks depending on immunosuppression		*Duration 6-12 weeks depending on immunosuppression
			**An RCT of [[itraconazole]] found that the relapse rate was significantly lower with 12 months of therapy compared to 6 months[[CiteRef::sehgal2022ef]]
	*Follow-up CT after a minimum of 2 weeks, or earlier if deterioration		*Follow-up CT after a minimum of 2 weeks, or earlier if deterioration
	*Non-pharmacologic management for neutropenic patients includes:		*Non-pharmacologic management for neutropenic patients includes:

Aidan at 20:08, 29 March 2022

2022-03-29T20:08:16Z

← Older revision		Revision as of 20:08, 29 March 2022
Line 428:		Line 428:
	*Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. ''Clin Microbiol Infect''. 2018. doi: [https://doi.org/10.1016/j.cmi.2018.01.002 10.1016/j.cmi.2018.01.002]		*Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. ''Clin Microbiol Infect''. 2018. doi: [https://doi.org/10.1016/j.cmi.2018.01.002 10.1016/j.cmi.2018.01.002]

	{{DISPLAYTITLE:''Aspergillus''		{{DISPLAYTITLE:''Aspergillus''}}
	[[Category:Hyaline molds]]		[[Category:Hyaline molds]]

Aidan: Text replacement - " species}}" to ""

2022-01-27T20:55:10Z

Text replacement - " species}}" to ""

← Older revision		Revision as of 20:55, 27 January 2022
Line 428:		Line 428:
	*Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. ''Clin Microbiol Infect''. 2018. doi: [https://doi.org/10.1016/j.cmi.2018.01.002 10.1016/j.cmi.2018.01.002]		*Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. ''Clin Microbiol Infect''. 2018. doi: [https://doi.org/10.1016/j.cmi.2018.01.002 10.1016/j.cmi.2018.01.002]

	{{DISPLAYTITLE:''Aspergillus'' ~~species}}~~		{{DISPLAYTITLE:''Aspergillus''
	[[Category:Hyaline molds]]		[[Category:Hyaline molds]]